Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018199593) BISPECIFIC ANTIBODY BINDING TO HER3 AND CD3
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/199593 International Application No.: PCT/KR2018/004743
Publication Date: 01.11.2018 International Filing Date: 24.04.2018
IPC:
C07K 16/28 (2006.01) ,C07K 16/32 (2006.01) ,A61K 47/68 (2017.01)
[IPC code unknown for C07K 16/28][IPC code unknown for C07K 16/32][IPC code unknown for A61K 47/68]
Applicants:
재단법인 목암생명과학연구소 MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH [KR/KR]; 경기도 용인시 기흥구 이현로 30번길 93 (보정동) (Bojeong-dong) 93, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924, KR
주식회사 녹십자 GREEN CROSS CORPORATION [KR/KR]; 경기도 용인시 기흥구 이현로 30번길, 107 (보정동) (Bojeong-dong) 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924, KR
Inventors:
김기수 KIM, Ki Su; KR
정준홍 JEONG, Jun Hong; KR
임형권 LIM, Hyung Kwon; KR
류재환 RYU, Jae Hwan; KR
권해냄 KWON, Hae Naem; KR
임양미 LIM, Yang Mi; KR
박용예 PARK, Yong Yea; KR
이은희 LEE, Eun Hee; KR
원종화 WON, Jong Hwa; KR
임옥재 LIM, Ok Jae; KR
신덕향 SHIN, Duck Hyang; KR
김문경 KIM, Mun Kyung; KR
이윤정 LEE, Yun Jung; KR
이지원 LEE, Jee Won; KR
남효정 NAM, Hyo Jung; KR
Agent:
두호특허법인 DOOHO IP LAW FIRM; 서울시 서초구 강남대로 51길 1, 7층 (서초동, 대현블루타워) (Daehyun Blue Tower, Seocho-dong) 7th Floor, 1, Gangnam-daero 51-gil, Seocho-gu, Seoul 06628, KR
Priority Data:
10-2017-005244924.04.2017KR
Title (EN) BISPECIFIC ANTIBODY BINDING TO HER3 AND CD3
(FR) ANTICORPS BISPÉCIFIQUE SE LIANT À HER3 ET CD3
(KO) HER3 및 CD3에 결합하는 이중특이적 항체
Abstract:
(EN) The present invention relates to a bispecific antibody binding to HER3 and CD3, the antibody comprising a first polypeptide of SEQ ID NO: 1, a second polypeptide of SEQ ID NO: 2, a third polypeptide selected from the group consisting of SEQ ID NOS: 3 and 5, and a fourth polypeptide selected from the group consisting of SEQ ID NOS: 4 and 6, and showing excellent effects of engaging immune cells specifically with HER3-positive cells and inducing the growth suppression and death of HER3-positive cells, without causing side effects attributed to non-specific cytotoxicity.
(FR) La présente invention concerne un anticorps bispécifique se liant à HER3 et CD3, l'anticorps comprenant un premier polypeptide de SEQ ID NO : 1, un deuxième polypeptide de SEQ ID NO : 2, un troisième polypeptide choisi dans le groupe constitué par SEQ ID NO : 3 et SEQ ID NO : 5, et un quatrième polypeptide choisi dans le groupe constitué par SEQ ID NO : 4 et SEQ ID NO : 6, et présentant d'excellents effets de mise en contact de cellules immunitaires spécifiquement avec des cellules HER3 positives, d'induction de la suppression de la croissance et d'induction de la mort des cellules HER3 positives, sans provoquer d'effets secondaires attribués à une cytotoxicité non spécifique.
(KO) 본 발명은 HER3 및 CD3에 결합하는 이중특이적 항체에 관한 것으로서, 서열번호 1의 제1폴리펩타이드, 서열번호 2 의 제2폴리펩타이드, 서열번호 3 및 5로 이루어진 군에서 선택되는 제3폴리펩타이드, 및 서열번호 4 및 6으로 이루어진 군에서 선택되는 제4폴리펩타이드를 포함함으로써 면역세포의 HER3-양성 세포에 대한 특이적 유도(engaging) 효과가 우수하고, HER3-양성 세포의 성장 억제 및 사멸 효과가 우수하며, 비특이적 세포 독성에 의한 부작용을 유발하지 않는 항체에 관한 것이다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)